Sustained Response of Three Pediatric BRAF Mutated High-grade Gliomas to Combined BRAF and MEK Inhibitor Therapy

Overview

Journal Oncotarget

Specialty Oncology

Date 2019 Feb 8

PMID 30728904

Citations 31

Authors

Stephanie A Toll

Hung N Tran

Jennifer Cotter

Alexander R Judkins

Benita Tamrazi

Jaclyn A Biegel

Girish Dhall

Nathan J Robison

Kaaren Waters

Palak Patel

Robert Cooper

Ashley S Margol

Affiliations

Soon will be listed here.

Abstract

Outcomes for children with high-grade gliomas (HGG) remain dismal despite aggressive treatment strategies. The use of targeted therapy for BRAF mutated malignancies including HGG is being explored as a potentially well tolerated and effective therapeutic option. The results of adult melanoma studies demonstrating that combination therapy with BRAF inhibitors and MEK inhibitors results in prolonged survival led us to employ this treatment strategy in children with BRAF mutated HGG. In this case series, we describe three pediatric patients with HGG with confirmed BRAF mutation who demonstrated responses to combination therapy with dabrafenib and trametinib.

Citing Articles

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation.

Steininger J, Buszello C, Oertel R, Meinhardt M, Schmid S, Engellandt K Acta Neuropathol Commun. 2024; 12(1):124.

PMID: 39107839 PMC: 11302837. DOI: 10.1186/s40478-024-01834-8.

Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.

Vo K, Sabnis A, Williams P, Roy-Chowdhuri S, Patton D, Coffey B JCO Precis Oncol. 2024; 8:e2400103.

PMID: 38935895 PMC: 11639582. DOI: 10.1200/PO.24.00103.

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.

Kardani K, Sanchez Gil J, Rabkin S Front Cell Infect Microbiol. 2023; 13:1206111.

PMID: 37325516 PMC: 10264819. DOI: 10.3389/fcimb.2023.1206111.

BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.

Muniz T, Mason W CNS Drugs. 2023; 37(7):587-598.

PMID: 37268805 DOI: 10.1007/s40263-023-01016-5.

Targeted treatment of solid tumors in pediatric precision oncology.

Bertacca I, Pegoraro F, Tondo A, Favre C Front Oncol. 2023; 13:1176790.

PMID: 37213274 PMC: 10196192. DOI: 10.3389/fonc.2023.1176790.

References

Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118(5):1739-49. PMC: 2289793. DOI: 10.1172/JCI33656. View

Emery C, Vijayendran K, Zipser M, Sawyer A, Niu L, Kim J . MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A. 2009; 106(48):20411-6. PMC: 2777185. DOI: 10.1073/pnas.0905833106. View

Hatzivassiliou G, Song K, Yen I, Brandhuber B, Anderson D, Alvarado R . RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010; 464(7287):431-5. DOI: 10.1038/nature08833. View

Poulikakos P, Zhang C, Bollag G, Shokat K, Rosen N . RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010; 464(7287):427-30. PMC: 3178447. DOI: 10.1038/nature08902. View

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C . Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121(3):397-405. DOI: 10.1007/s00401-011-0802-6. View

Cohen K, Pollack I, Zhou T, Buxton A, Holmes E, Burger P . Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011; 13(3):317-23. PMC: 3064602. DOI: 10.1093/neuonc/noq191. View

Wagle N, Emery C, Berger M, Davis M, Sawyer A, Pochanard P . Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011; 29(22):3085-96. PMC: 3157968. DOI: 10.1200/JCO.2010.33.2312. View

Poulikakos P, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G . RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480(7377):387-90. PMC: 3266695. DOI: 10.1038/nature10662. View

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O . RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3):207-15. PMC: 3724537. DOI: 10.1056/NEJMoa1105358. View

10.

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

11.

Hauschild A, Grob J, Demidov L, Jouary T, Gutzmer R, Millward M . Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839):358-65. DOI: 10.1016/S0140-6736(12)60868-X. View

12.

Flaherty K, Infante J, Daud A, Gonzalez R, Kefford R, Sosman J . Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18):1694-703. PMC: 3549295. DOI: 10.1056/NEJMoa1210093. View

13.

Myung J, Cho H, Park C, Kim S, Lee S, Park S . Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. Transl Oncol. 2013; 5(6):430-6. PMC: 3542839. DOI: 10.1593/tlo.12328. View

14.

Kleinschmidt-DeMasters B, Aisner D, Birks D, Foreman N . Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol. 2013; 37(5):685-98. PMC: 4610349. DOI: 10.1097/PAS.0b013e31827f9c5e. View

15.

Chen Y, Gutmann D . The molecular and cell biology of pediatric low-grade gliomas. Oncogene. 2013; 33(16):2019-26. DOI: 10.1038/onc.2013.148. View

16.

Chamberlain M . Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol. 2013; 114(2):237-40. DOI: 10.1007/s11060-013-1176-5. View

17.

Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L . Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2013; 61(6):1101-3. DOI: 10.1002/pbc.24891. View

18.

Robinson G, Orr B, Gajjar A . Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer. 2014; 14:258. PMC: 3996187. DOI: 10.1186/1471-2407-14-258. View

19.

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20):1877-88. DOI: 10.1056/NEJMoa1406037. View

20.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View